RRAJASTHAN NEWS 24News that matters

Home / USA / FDA and Cancer Treatment

HEALTHCARE · FDA APPROVAL

FDA Approves Rybrevant Faspro for Certain Advanced Head and Neck Cancers

Editorial illustration of a medical treatment vial, clinical-trial chart and healthcare cross.
Editorial illustration. Editorial illustration of a medical treatment vial, clinical-trial chart and healthcare cross.

The FDA granted accelerated approval to Rybrevant Faspro for certain adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum chemotherapy and immunotherapy.

SILVER SPRING, MARYLAND, November 6, 2026: The FDA granted accelerated approval to Rybrevant Faspro for certain adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum chemotherapy and immunotherapy.

The U.S. Food and Drug Administration granted accelerated approval on November 5 to Rybrevant Faspro, a combination of amivantamab and hyaluronidase-lpuj, for certain adults with recurrent or metastatic head and neck squamous cell carcinoma. The treatment is intended for patients whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody.

What the trial found

The FDA said the approval was based on an open-label, multicenter study involving 102 patients. The overall response rate was 42%, meaning tumors decreased in size or disappeared in that share of participants. Among patients who responded, 56% had a response lasting at least six months.

The agency said currently approved therapies in this setting have response rates around 20% or less. These results describe tumor response in the study population; they do not mean every patient will benefit or that the treatment is a cure.

Why the approval is accelerated

Accelerated approval allows the FDA to make certain medicines available earlier for serious conditions using a surrogate or intermediate endpoint. The agency said it has not yet been confirmed whether the observed response translates into a clinically meaningful long-term benefit. Confirmatory studies are required to verify clinical benefit.

Important safety and eligibility details

The FDA said the treatment is not indicated for HPV-associated oropharyngeal squamous cell carcinoma. It highlighted warnings involving hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, skin reactions, eye toxicity and potential harm to an unborn baby. Patients should review the full prescribing information with their oncology team.

Sources and further reading

Editorial note: This is an accelerated approval based on response rate and duration of response. The FDA requires confirmatory studies to verify clinical benefit.

Related coverage: Latest U.S. news · Business and finance news

← Back to U.S. news · Business and finance coverage